Differentiating leukemia subtypes based on metabolic signatures using hyperpolarized 13 C NMR.

Autor: Christensen NV; The MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Laustsen C; The MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Bertelsen LB; The MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: NMR in biomedicine [NMR Biomed] 2024 Dec; Vol. 37 (12), pp. e5264. Date of Electronic Publication: 2024 Sep 25.
DOI: 10.1002/nbm.5264
Abstrakt: Leukemia is a group of blood cancers that are classified in four major classes. Within these four classes, many different subtypes exists with similar origin, genetic mutations, and level of maturity, which can make them difficult to distinguish. Despite their similarities, they might respond differently to treatment, and therefore distinguishing between them is of crucial importance. A deranged metabolic phenotype (Warburg effect) is often seen in cancer cells, leukemia cells included, and is increasingly a target for improved diagnosis and treatment. In this study, hyperpolarized 13 C NMR spectroscopy was used to characterize the metabolic signatures of the six leukemia cell lines ML-1, CCRF-CEM, THP-1, MOLT-4, HL-60, and K562. This was done using [1- 13 C]pyruvate and [1- 13 C]alanine as bioprobes for downstream metabolite quantification and kinetic analysis on cultured cells with and without 2-deoxy-D-glucose treatment. The metabolic signatures of similar leukemia subtypes could be readily distinguished. This includes ML-1 and THP-1, which are of the similar M4 and M5 AML subtypes, CCRF-CEM and MOLT-4, which are of the similar T-ALL lineage at different maturation states, and HL-60 and K562, which are of the closely related M1 and M2 AML subtypes. The data presented here demonstrate the potential of hyperpolarized 13 C NMR spectroscopy as a method to differentiate between leukemia subtypes of similar origin. Combining this method with bioreactor setups could potentially allow for better leukemia disease management as metabolic signatures could be acquired from a single biopsy through repeated experimentation and intervention.
(© 2024 The Author(s). NMR in Biomedicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: